NEEDHAM, Mass. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced that

Chiasma advances U.S. commercial launch originally planned for fourth quarter NEEDHAM, Mass. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of

NEEDHAM, Mass. , Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the online

MYCAPSSA ®   U.S. commercial launch planned for the fourth quarter On track to announce MPOWERED Phase 3 trial topline data in the fourth quarter Company to host conference call today, August 10 , at 5pm ET NEEDHAM, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc.

Company to host conference call and webcast at 5:00 p.m. ET NEEDHAM, Mass. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 5:00

-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within normal limits at the end of the 48-week OLE period -- -- All MYCAPSSA responders

NEEDHAM, Mass. , July 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the burden of

NEEDHAM, Mass. , June 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the burden of

MYCAPSSA is indicated for long-term maintenance treatment in acromegaly   patients who have   responded to and tolerated treatment with octreotide or lanreotide Conference call and webcast scheduled today at 2 pm ET NEEDHAM, Mass. , June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc.

Remain on Track with MYCAPSSA® Anticipated June 26, 2020 PDUFA Date and Planned U.S. Commercial Launch in Q4’20 NEEDHAM, Mass. , May 07, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients who face

Company to host conference call and webcast at 5:00 p.m. ET NEEDHAM, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it

NEEDHAM, Mass. , April 22, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases, today announced the

NEEDHAM, Mass. , April 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced its entry into a revenue interest financing agreement with HealthCare

MYCAPSSA ® PDUFA Date Set for June 26, 2020 ; U.S. Commercial Launch Planned in Q4’20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass. , March 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical stage biopharmaceutical

Company to host conference call and webcast at 5:00 p.m. ET NEEDHAM, Mass. , March 09, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will

FDA sets PDUFA date of June 26, 2020 Acceptance follows December 26, 2019 NDA resubmission NEEDHAM, Mass. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases,

MYCAPSSA ® NDA resubmitted to FDA ; PDUFA decision expected mid-2020 MYCAPSSA ® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA ® MPOWERED Phase 3 results on track for the fourth quarter of 2020 NEEDHAM, Mass. , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc.